SCHEDULE 13G: BlackRock Discloses 6.5% Stake in Ginkgo Bioworks Holdings
Beneficial Ownership Disclosure
BlackRock, Inc. has disclosed a 6.5% beneficial ownership stake in Ginkgo Bioworks Holdings, Inc., holding over 3 million shares of common stock.
Summary
- BlackRock, Inc. reported beneficial ownership of 3,001,643 shares of Ginkgo Bioworks Holdings, Inc. common stock.
- This ownership represents 6.5% of the total outstanding common stock of Ginkgo Bioworks Holdings, Inc.
- BlackRock, Inc. holds sole voting power over 2,916,224 shares and sole dispositive power over 3,001,643 shares.
- The filing was made as a Schedule 13G, indicating that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing control of the issuer.
- The beneficial ownership is attributed to various business units of BlackRock, Inc. and its subsidiaries and affiliates, with one or more entities beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 6
Explanation: The disclosure of a significant stake by a major institutional investor like BlackRock is generally viewed as a neutral to slightly positive signal, indicating institutional interest in the company.
Positives
- The disclosure of a significant stake by a major institutional investor like BlackRock, Inc. can signal confidence in Ginkgo Bioworks Holdings, Inc.'s long-term prospects.
Future Outlook
NA
Industry Context
Ginkgo Bioworks Holdings, Inc. operates in the synthetic biology and biotechnology sector, focusing on programming cells for various applications. BlackRock, Inc. is one of the world's largest asset managers, and its significant stake reflects its investment strategy across diverse industries.
Stakeholder Impact
- Shareholders: Provides transparency regarding significant institutional ownership, potentially influencing investor confidence and trading activity.
Key Dates
| Date | Description |
|---|---|
| 01/21/2025 | Date of execution of the Power of Attorney by BlackRock, Inc. |
| 06/30/2025 | Date of event which required the filing of this statement. |
| 07/17/2025 | Date the Schedule 13G was signed by BlackRock, Inc. |
Keywords
BlackRock, Ginkgo Bioworks Holdings, SEC Filing, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, Biotechnology, Synthetic Biology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.